Psychopharmacology Update 2021

Download All
This comprehensive program includes a current review of diagnostic and therapeutic issues and options and explores innovative treatment approaches in patients with various psychiatric conditions such as mood and anxiety disorders, schizophrenia, and ADHD. Premenstrual, perinatal, and perimenopausal depression are also covered. Learners can access webcasts and downloadable slides for future reference and use.
Anita Clayton, MD
Joseph F. Goldberg, MD
John M. Kane, MD
Sanjay J. Mathew, MD
Greg W. Mattingly, MD
Roger McIntyre, MD, FRCPC
Jonathan M. Meyer, MD
Anthony L. Rostain, MD, MA
Manpreet K. Singh, MD, MS

Downloadable Slidesets

This presentation on pharmacotherapy of major depression will review the differences between major depressive disorder and other psychiatric disorders, unmet needs in major depressive disorder, the traditional treatment approaches for major depressive disorder and their limitations, and novel approaches to treatment of major depressive disorder and their adverse event profiles.

Manpreet K. Singh, MD, MS Released: December 7, 2021

This presentation on pharmacotherapy of schizophrenia will review the role of shared decision-making, considerations in balancing efficacy and tolerability, the role of maintenance treatment, whether long-acting formulations help in reducing relapse risk, and when clozapine is indicated.

John M. Kane, MD Released: December 8, 2021

Anxiety disorders are among the most prevalent mental disorders. Approximately 1 in 4 adults will suffer from an anxiety disorder at some point in their lives. Slides from a presentation on the pharmacotherapy of anxiety disorders detail therapeutic medication options.

Sanjay J. Mathew, MD Released: December 8, 2021

These slides are from a presentation that identifies strategies for recognizing plausible cause-and-effect relationships between physical complaints and suspected adverse drug events, recognizes patient-specific risk factors for particular adverse drug events, and describes evaluation and management strategies for common adverse events associated with psychotropic drugs.

Joseph F. Goldberg, MD Released: December 8, 2021

This presentation on pharmacotherapy of antipsychotic-induced movement disorders will review incorporating into practice the 2021 American Psychiatric Association recommendations on managing antipsychotic-induced parkinsonism, acute dystonia, akathisia, and TD; the rationale for avoiding routine or prolonged anticholinergic use to manage antipsychotic-related parkinsonism or dystonia; the latest recommendations on effective TD management; and the differences in deutetrabenazine and valbenazine, the VMAT2 inhibitors that are approved by the FDA for TD.

Jonathan M. Meyer, MD Released: December 8, 2021

One of the most important needs in treating bipolar disorder is a proper diagnosis, where screening tools such as the Rapid Mood Screener can help. Second-generation antipsychotics have the most data in mixed features, and only lumateperone and quetiapine have proven efficacy data in bipolar II depression. Antidepressants may be safe and effective in certain patients, particularly those with bipolar II. Rapid-acting antidepressants such as ketamine are currently being studied.

Roger McIntyre, MD, FRCPC Released: December 7, 2021

This presentation on pharmacotherapy of ADHD reviews the prevalence and diagnosis of comorbid ADHD with other psychiatric conditions; differences in symptoms that occur in children, adolescents, and adults; potential for medication misuse in psychiatric patients with comorbid ADHD; and treatment options including new advances.

Anthony L. Rostain, MD, MA Released: December 8, 2021

This presentation on pharmacotherapies for psychiatric disorders will review new and novel pharmacologics, including those currently in the clinic, in the pipeline, and treatments of the future. Covered topics include: depression, schizophrenia, bipolar, and ADHD.

Greg W. Mattingly, MD Released: December 8, 2021

These slides are from a presentation that articulates the criteria for diagnosis of PMDD and options for treatment, describes prevalence of depression in pregnancy and postpartum and management considerations related to pregnancy and breastfeeding, utilizes the Edinburgh Postnatal Depression Scale to screen for depressive symptoms in perinatal and postpartum women, and explains the factors important in identification and treatment of perimenopausal depression.

Anita Clayton, MD Released: December 8, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings